factual

Shkreli Used Distribution To Block Off-Patent Generic

Martin Shkreli raised an off-patent drug from $13.50 to $750 a tablet and, although the drug had no REMS safety protocol, his company unilaterally declared it would distribute only through certain safety protocols and distributors—an FDA-unrequested move designed to deny generics a sample and create a competition-free zone, with an executive admitting they wouldn't make it easier for generics.

factualpending

Speaker

Robin Feldman

Evidence Quote

“Shkreli and his company declared that they would only distribute it through certain safety protocols and through certain types of distributors. The FDA hadn't even asked them: they simply declared”

Source

Robin Feldman on Drug Patents, Generics, and Drug Wars— EconTalk
Created: 6/13/2026, 12:11:23 AM

Your notes

Loading notes...